Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Vaspin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Visceral adipose-specific serpin, Serpin A12, Visceral adipose tissue-derived serine protease inhibitor, OL-64, SERPINA12
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD191097200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-Heparin

Sample Requirements

80 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.031–2 ng/ml

Limit of Detection

0.01 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 7.6%

Inter-assay (Run-to-Run)

n = 6; CV = 7.7%

Spiking Recovery

91,50%

Dilutation Linearity

100,10%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • monkey Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
Summary

Features

  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures vaspin in serum and plasma (EDTA, heparin)
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Quality Controls are human serum based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Reproduction

Summary

Visceral adipose tissue – derived serpin A12 (vaspin), also named OL-64, an adipocytokine, is structurally a member of the serine protease family. Serpins are the most diverse family of protease inhibitors. Their typical structural feature is the core domain composed from 3 beta-sheets and 9 alpha-helixes. The inhibitory activity of vaspin has not been described up to now, but its reactive site loop is typical for this proteinase family. Human Vaspin protein is composed of 395 amino acids and has a molecular weight of approximately 45.2 kDa and predicted pI 9.26. The cDNA was first isolated from white adipose tissue of Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Vaspin mRNA expression is specific for visceral adipose tissues and it is also found circulating in the serum. The level of serum vaspin increased with age up to the peak of obesity, body weight and insulin resistance in OLETF rats and decreases with worsening of diabetes. Vaspin expression is missing in the diabetes-resistant lean rats, LETO, in comparison to OLEFT rats, animal model of metabolic syndrome. Expression was also absent in the subdermal, brown fatty tissue and other non-adipose tissues in OLEFT rats. These findings lead to the conclusion that the target tissue for insulin sensitising effect of vaspin is white adipose tissue. In humans, elevated serum concentration of vaspin is associated with obesity and impaired insulin sensitivity. In patients with type 2 diabetes the correlation between increased vaspin levels and BMI and decreased insulin sensitivity has not been observed. Vaspin expression decreased when diabetes worsened and its levels normalised when insulin or pioglitazone was administered. Gender differences in vaspin serum levels have been found in separate studies by two different authors. The low levels of vaspin in serum seem to be typical for lean subjects and athletes with long-term physical training. On the other hand, serum vaspin concentration increased in overweight people after they lost weight because of increased exercise. This paradox has been explained by the fact that serum vaspin level is differentially regulated in the non-active resting state and after exercise.

References to Product

References

  • Dimova R, Tankova T, Kirilov G, Chakarova N, Dakovska L, Grozeva G. Is vaspin related to cardio-metabolic status and autonomic function in early stages of glucose intolerance and in metabolic syndrome?. Diabetol Metab Syndr. 2016;8:46
  • Kafalidis G, Boutsikou T, Briana DD, Boutsikou M, Marmarinos A, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A. Adipokines vaspin and omentin-1 are up-regulated in large for gestational age infants at term. Cytokine. 2013 Apr;62 (1):70-4
  • Kiskac M, Zorlu M, Akkoyunlu ME, Kilic E, Karatoprak C, Cakirca M, Yavuz E, Ardic C, Camli AA, Cikrikcioglu M, Kart L. Vaspin and lipocalin-2 levels in severe obsructive sleep apnea. J Thorac Dis. 2014 Jun;6 (6):720-5
  • Mierzyński R, Poniedziałek-Czajkowska E, Dłuski D, et al. Nesfatin-1 and Vaspin as Potential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus. Int J Mol Sci. 2019;20(1):159. Published 2019 Jan 4. doi:10.3390/ijms20010159
  • Ostrowska Z, Ziora K, Oświęcimska J, Świętochowska E, Marek B, Kajdaniuk D, Strzelczyk J, Gołąbek K, Morawiecka-Pietrzak M, Wołkowska-Pokrywa K, Kos-Kudła B. Vaspin and selected indices of bone status in girls with anorexia nervosa. Endokrynol Pol. 2016;67(6):599-606. doi: 10.5603/EP.2016.0070
  • Wu L, Piotrowski K, Rau T, Waldmann E, Broedl UC, Demmelmair H, Koletzko B, Stark RG, Nagel JM, Mantzoros CS, Parhofer KG. Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism. 2014 Mar;63 (3):382-91
  • Wyskida K, Franik G, Wikarek T, et al. The levels of adipokines in relation to hormonal changes during the menstrual cycle in young, normal-weight women. Endocr Connect. 2017;6(8):892-900.
References to Summary

References to Vaspin

  • Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005 Jul 26;102 (30):10610-5
  • Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006 Jan 6;339 (1):430-6
  • Li Q, Chen R, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J Int Med Res. 2008 Jul-Aug;36 (4):625-9
  • Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008 Jan;93 (1):247-51
  • Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes. 2008 Jun;57 (6):1501-7
  • Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008 Mar;17 (3):327-33
  • Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008 Feb;57 (2):372-7
Related Products Documents